Xinxiang Tuoxin Pharmaceutical Co.Ltd. - Asset Resilience Ratio

Latest as of March 2026: 7.00%

Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) has an Asset Resilience Ratio of 7.00% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥115.56 Million

≈ $16.91 Million USD Cash + Short-term Investments

Total Assets

CN¥1.65 Billion

≈ $241.59 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 301089 total asset value.

Liquid Assets Composition Over Time

This chart breaks down Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 301089 total debt and obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥115.56 Million	7.0%
Total Liquid Assets	CN¥115.56 Million	7.00%

Asset Resilience Insights

Limited Liquidity: Xinxiang Tuoxin Pharmaceutical Co.Ltd. maintains only 7.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Xinxiang Tuoxin Pharmaceutical Co.Ltd. Industry Peers by Asset Resilience Ratio

Compare Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Yunnan Baiyao Group Co Ltd SHE:000538	Drug Manufacturers - Specialty & Generic	8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Harbin Gloria Pharmaceuticals SHE:002437	Drug Manufacturers - Specialty & Generic	9.04%
Jiuzhitang Co Ltd SHE:000989	Drug Manufacturers - Specialty & Generic	7.86%
Renhe Pharmacy Co Ltd SHE:000650	Drug Manufacturers - Specialty & Generic	37.54%
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	Drug Manufacturers - Specialty & Generic	0.29%

Annual Asset Resilience Ratio for Xinxiang Tuoxin Pharmaceutical Co.Ltd. (2021–2025)

The table below shows the annual Asset Resilience Ratio data for Xinxiang Tuoxin Pharmaceutical Co.Ltd..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	6.31%	CN¥105.15 Million ≈ $15.39 Million	CN¥1.67 Billion ≈ $243.69 Million	-7.95pp
2024-12-31	14.27%	CN¥250.88 Million ≈ $36.71 Million	CN¥1.76 Billion ≈ $257.29 Million	+3.90pp
2023-12-31	10.37%	CN¥190.70 Million ≈ $27.91 Million	CN¥1.84 Billion ≈ $269.10 Million	-2.66pp
2022-12-31	13.03%	CN¥240.16 Million ≈ $35.14 Million	CN¥1.84 Billion ≈ $269.73 Million	-2.80pp
2021-12-31	15.83%	CN¥220.62 Million ≈ $32.28 Million	CN¥1.39 Billion ≈ $203.94 Million	--

pp = percentage points

About Xinxiang Tuoxin Pharmaceutical Co.Ltd.

SHE:301089 China Drug Manufacturers - Specialty & Generic

Market Cap

$414.24 Million

CN¥2.83 Billion CNY

Market Cap Rank

#13334 Global

#3979 in China

Share Price

CN¥22.37

Change (1 day)

+1.64%

52-Week Range

CN¥19.99 - CN¥34.47

All Time High

CN¥209.98